Know Cancer

or
forgot password

Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy


Phase 3
50 Years
80 Years
Not Enrolling
Male
Risk of Bone Fracture Occurrences

Thank you

Trial Information

Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy


Inclusion Criteria:



- give voluntary signed informed consent

- have histologically documented prostate cancer

- have been on ADT treatment for 6 months prior to randomization or intermittent LHRHa
for preceeding 12 months

- expected to continue LHRHa therapy uninterrupted for the next 12 months

- have total testosterone levels less than 50 ng/dL

- Have BMD of lumbar spine or femoral neck at or below the BMD thresholds

- have a Zubrod performance status
- subject weight <300 lbs(<136 kg)

- agree to complete a daily diary of medication intake

- agree not to take excluded medications throughout the trial

- agree to use an effective method of contraception

- have adequate bone marrow, liver and renal functions

Exclusion Criteria:

- Currently or previously exposed

- within the past 5 years to intravenous bisphosphonates, strontium ranelate or
Denosumab

- for more than 3 years to oral bisphosphonates

- within the last 45 days to PTH or PTH derivative, anabolic steroids or testosterone,
SERMs, calcitonin, calcitriol or oral gluccorticoids

- have any disease or condition that would preclude an accurate evaluation of
radiographs of the thoracic or lumbar spine

- have <8 evaluable vertebrae

- have a BMD T score <-4 at the lumbar spine or total hip or femoral neck

- have any history of other carcinomas within the last 5 years

- Serum PSA > 5ng/mL at baseline under ADT

- have Paget's disease, Cushing's disease, chronic hepatitis or cirrhosis or rheumatoid
arthritis

- have active uncontrolled systemic viral, bacterial or fungal infections

- have a clinically significant concurrent illness or psychological, familial,
sociological, geograhical or other condition that would not permit adequate follow-up
and compliance

- received treatment with other investigational agents within 30 days

- taking finasteride, dutasteride, danazol or testosterone like substances

- taking herbal medicines or dietary supplements

- have a history of thromboembolic disease including DVT or pulmonary embolus

- have a QTcF of > or equal to 450 msec or congenital or acquired QTc prolongation

- have HIV

- calcicum urolithiasis prohibiting the use of vitamin D

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Outcome Measure:

To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures

Outcome Time Frame:

36 months

Safety Issue:

No

Principal Investigator

Michael Brawer, MD

Investigator Role:

Study Director

Investigator Affiliation:

GTx

Authority:

United States: Food and Drug Administration

Study ID:

G300213

NCT ID:

NCT01214291

Start Date:

March 2011

Completion Date:

September 2015

Related Keywords:

  • Risk of Bone Fracture Occurrences
  • fractures
  • prostate cancer
  • androgen deprivation therapy
  • Fractures, Bone
  • Prostatic Neoplasms

Name

Location

VA Puget SoundSeattle, Washington  98108